Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Craig-Hallum raised the firm’s price target on CVRx (CVRX) to $22 from $20 and keeps a Buy rating on the shares. CVRx posted a modest beat in ...

Craig-Hallum raised the price target on CVRx Inc (NASDAQ:CVRX) shares to $22.00 from $20.00, maintaining a Buy rating on the company's shares. The adjustment came after CVRx reported a modest beat in ...

William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...

Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%Full year revenue expected to ...

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on CVRx (CVRX – Research Report). The company’s ...

CVRx anticipates a 35% increase in Q4 2024 revenue and a 30% increase in FY24 revenue, with shares down 1.55% premarket.

CVRx (NASDAQ:CVRX) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...

CVRx, Inc. (NASDAQ:CVRX), a biomedical devices company with a market capitalization of $331.2 million specializing in the treatment of heart failure and hypertension through its innovative ...

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the United States, Germany ...